KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors
01 May, 2021
– Vizgen from Cambridge, MA develops genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease with spatial context.
– Series B $37m round was led by Novalis LifeSciences LLC and current investor Northpond Ventures with participation from new investors Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund, and current investors ARCH Venture Partners and David Walt, Ph.D., Professor at Harvard Medical School, Core Faculty at the Wyss Institute, and co-founder of Vizgen.
– The company intends to use the funds to accelerate growth and infrastructure expansion leading up to full commercial launch.